Celgene Raises Guidance as Sales of Top Drug Revlimid Grow

  • 2016 adjusted earnings will be $5.70 to $5.75 a share
  • Blood cancer pill’s sales grow by 18 percent from year before

Celgene Corp. raised its full-year guidance after the drugmaker’s second-quarter profit beat analysts’ estimates on higher sales of Revlimid, a pill for blood cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.